Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
BPQ-OH inhibits L. amazonensis growth, may help development of anti-Leishmania agents
February 8th, 2006
3-(biphenyl-4-yl)-3-hydroxyquinuclidine (BPQ-OH) appears to be a potent growth inhibitor of Leishmania amazonensis (L. amazonensis), and may be a valuable lead compound for the development of novel anti-Leishmania agents. According to recent research published in the journal Experimental Parasitology, "Parasites of the Leishmania genus require for the growth and viability the de novo synthesis of specific sterols as such as episterol and 5-dehydroepisterol because cholesterol, which is abundant in their mammalian hosts, does not fulfill the parasite sterol requirements. Squalene synthase catalyzes the first committed step in the sterol biosynthesis...
Source: Immunotherapy Weekly (2006-02-08)
|
